GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Beneish M-Score

ABL Bio (XKRX:298380) Beneish M-Score : 5.15 (As of May. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 5.15 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for ABL Bio's Beneish M-Score or its related term are showing as below:

XKRX:298380' s Beneish M-Score Range Over the Past 10 Years
Min: -4.09   Med: 0.49   Max: 11.5
Current: 5.15

During the past 8 years, the highest Beneish M-Score of ABL Bio was 11.50. The lowest was -4.09. And the median was 0.49.


ABL Bio Beneish M-Score Historical Data

The historical data trend for ABL Bio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Beneish M-Score Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -1.92 2.27 -4.09 5.11 -1.65

ABL Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.42 0.69 -3.53 -1.65 5.15

Competitive Comparison of ABL Bio's Beneish M-Score

For the Biotechnology subindustry, ABL Bio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Bio's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABL Bio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ABL Bio's Beneish M-Score falls into.



ABL Bio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ABL Bio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 9.1181+0.528 * 1+0.404 * 0.1025+0.892 * 0.3159+0.115 * 8.563
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.54+4.679 * 0.153477-0.327 * 1.0492
=5.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ₩248 Mil.
Revenue was 7937.206 + 8004.697 + 8570.734 + 8590.309 = ₩33,103 Mil.
Gross Profit was 7937.206 + 8004.697 + 8570.734 + 8590.309 = ₩33,103 Mil.
Total Current Assets was ₩56,459 Mil.
Total Assets was ₩140,758 Mil.
Property, Plant and Equipment(Net PPE) was ₩77,619 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩2,582 Mil.
Selling, General, & Admin. Expense(SGA) was ₩9,596 Mil.
Total Current Liabilities was ₩32,725 Mil.
Long-Term Debt & Capital Lease Obligation was ₩43,071 Mil.
Net Income was -11971.109 + -12513.49 + -4109.451 + -10358.336 = ₩-38,952 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0 Mil.
Cash Flow from Operations was -17518.966 + -17343.828 + -11665.697 + -14027.006 = ₩-60,555 Mil.
Total Receivables was ₩86 Mil.
Revenue was 40381.314 + 9904.013 + 38378.288 + 16139.488 = ₩104,803 Mil.
Gross Profit was 40381.314 + 9904.013 + 38378.288 + 16139.488 = ₩104,803 Mil.
Total Current Assets was ₩102,600 Mil.
Total Assets was ₩202,901 Mil.
Property, Plant and Equipment(Net PPE) was ₩6,391 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩2,433 Mil.
Selling, General, & Admin. Expense(SGA) was ₩8,582 Mil.
Total Current Liabilities was ₩103,724 Mil.
Long-Term Debt & Capital Lease Obligation was ₩410 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(247.793 / 33102.946) / (86.025 / 104803.103)
=0.007486 / 0.000821
=9.1181

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(104803.103 / 104803.103) / (33102.946 / 33102.946)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (56459.415 + 77618.775) / 140758.067) / (1 - (102599.621 + 6391.344) / 202901.27)
=0.047456 / 0.462837
=0.1025

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=33102.946 / 104803.103
=0.3159

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2432.754 / (2432.754 + 6391.344)) / (2582.182 / (2582.182 + 77618.775))
=0.275694 / 0.032196
=8.563

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9595.69 / 33102.946) / (8581.801 / 104803.103)
=0.289874 / 0.081885
=3.54

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((43070.554 + 32724.507) / 140758.067) / ((409.916 + 103723.979) / 202901.27)
=0.538478 / 0.513224
=1.0492

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-38952.386 - 0 - -60555.497) / 140758.067
=0.153477

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ABL Bio has a M-score of 5.15 signals that the company is likely to be a manipulator.


ABL Bio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ABL Bio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Bio (XKRX:298380) Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines